Chim Lang

Professor

University of Dundee

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Chim Lang is a faculty member at the University of Dundee in the United Kingdom. His research focuses on heart failure, metabolic dysfunction, and the genetic underpinnings of conditions such as type 2 diabetes. Recent publications include studies on participant recruitment strategies for clinical trials and the clinical effectiveness of self-care rehabilitation interventions. He is actively engaged in understanding the complexities of cardiovascular health and its implications for patient care.

Articles (30)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (24)

Patrick Doherty

University of York

UNITED KINGDOM

Chim Lang

Research Interests

Explore related searches

Contact this professor

About

Articles (30)

Genome-wide association study meta-analysis provides insights into the etiology of heart failure and its subtypes

Evidence-based enhanced participant information sheet for recruiting carers to the REACH-HFpEF multicentre randomized trial

Guideline-directed medical strategies for the co-management of heart failure and metabolic dysfunction-associated steatotic liver disease

Effect of Frailty on Cardiovascular Clinical Trials

Genetics of type 2 diabetes (T2D) in Malaysia: a review

Understanding the self-management experiences of people with heart failure with preserved ejection fraction (HFpEF), their caregivers and the health care professionals who support them

Emerging imaging and circulating biomarkers in relation to underlying mechanisms in Bicuspid Aortic Valve aortopathy

Heart Failure With Preserved Ejection Fraction Phenotype Is Associated With Early Symptom Onset in Aortic Stenosis and Residual Symptoms After Transcatheter Aortic Valve Implantation

Morbidity After Takotsubo Syndrome: A Report From the Scottish Takotsubo Registry

Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial.

Heart failure with improved versus persistently reduced left ventricular ejection fraction

Limiting Extracellular Matrix Expansion in Diet-Induced Obese Mice Reduces Cardiac Insulin Resistance and Prevents Myocardial Remodelling

Dapagliflozin, Inflammation and Left Ventricular Remodelling in Patients with Type 2 Diabetes and Left Ventricular Hypertrophy

Artificial intelligence-assisted automated heart failure detection and classification from electronic health records

Differential biomarker expression in heart failure patients with and without mitral regurgitation

Accelerated elastin degradation by age-disease interaction

Clinical characteristics and prognosis of patients with heart failure and high concentrations of interleukin-17D

Cardiovascular and Noncardiovascular Prescribing and Mortality After Takotsubo

Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure

The impact of ferric derisomaltose on cardiovascular and non-cardiovascular events in patients with anemia, iron deficiency and heart failure with reduced ejection fraction.

Distinct pathophysiological pathways in women and men with heart failure

Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure

Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF

Letter by Singh et al Regarding Article, “Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)”

The value of spot urinary creatinine as a marker of muscle wasting in patients with new‐onset or worsening heart failure

A facilitated home-based cardiac rehabilitation intervention for people with heart failure and their caregivers: a research programme including the REACH-HF RCT

Metformin: still the sweet spot for CV protection in diabetes?

Effect of the 2017 European Guidelines on Reclassification of Severe Aortic Stenosis and Its Influence on Management Decisions for Initially Asymptomatic Aortic Stenosis

Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure

Collaborators (24)

Patrick Doherty

Christi Deaton

Christian Cole

Robin Ray

Dana Dawson

Colin Palmer

Faisel Khan

Colin Murdoch

Valerie Smith

Leong Ng

Charlotte Bolton

Mohsen Ghanbari

John Cleland

Anna Maria Choy

Alexander Doney

Ify Mordi

Li Kang

Graham Rena

Sundararajan Srinivasan

Anvesha Singh

Iziah E. Sama

Doug Speed

Joseph Dowsett

Hasnain Dalal

Make your next move.